Our work is entirely funded by private donations – we receive no money from government. Your money will help us continue funding research into vitiligo and supporting people affected by the condition.
FB102 antibody treatment for nonsegmental vitiligo
Official title: A Randomized, Double-Blind, Placebo Controlled, Multi-center Study to Evaluate the Safety and Efficacy of FB102 in Patients With Non-Segmental Vitiligo
Status: Recruiting now
Description:
Forte Biosciences, Inc. plans to enroll about 64 participants. FB102 is an experimental antibody that targets CD122 and changes IL-2 and IL-15 immune signaling. It is intended to reduce disease-driving T-cell activity so melanocytes can recover and repigment the skin. Possible risks include infusion reactions, headache, and infections; early studies have mainly reported mild or moderate events. People ages 18 to 75 may qualify. The study is recruiting at 6 listed sites in Australia, and New Zealand.
Start date: March 25, 2025
Completion date: December 31, 2026
Organizer: Forte Biosciences, Inc.
Contact: Cindy Kok
Tel.: +61 2 8651 2042
Email: ckok@skinhospital.edu.au
Clinical Trial Alerts
Sign up and be the first to know about updates on this trial.
FAQOther Questions
- Polypodium leucotomos as an adjunct treatment for vitiligo?
The tropical fern Polypodium leucotomos (also known as Polypodium aureum) and its relative Polypodium decumanumhave shown potential benefits for managing vitiligo and other auto...
- What's the status with official recognition of World Vitiligo Day?
In 2016, the United Nations marked World Vitiligo Day in its International Calendar of Disability Events. However, it was removed in 2019 when the calendar was streamlined to 'M...
- What are the best predictors for therapy response in vitiligo?
A fair question. Also a slightly annoying one, because dermatology loves nuance and patients usually want something more like a weather forecast. Still, a few factors do show up...
Though it is not always easy to treat vitiligo, there is much to be gained by clearly understanding the diagnosis, the future implications, treatment options and their outcomes.
Many people deal with vitiligo while remaining in the public eye, maintaining a positive outlook, and having a successful career.
Copyright (C) Bodolóczki JúliaBy taking a little time to fill in the anonymous questionnaire, you can help researchers better understand and fight vitiligo.